Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences
November 12 2020 - 8:00AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver
disease company developing novel bile acid modulators, today
announced that Ron Cooper, President and Chief Executive Officer,
will present via webcast at the 2020 Jefferies London Healthcare
Conference on November 19 at 12 p.m. EST. The Company will also be
participating in the virtual Piper Sandler 32nd Annual Healthcare
Conference being held December 1-3.
A live audio webcast of the Jefferies presentation will be
accessible from the Albireo Media & Investors page
(http://ir.albireopharma.com/) and will be archived and available
for replay on Albireo’s website for two weeks following the
event.
About AlbireoAlbireo Pharma is a
clinical-stage biopharmaceutical company focused on the development
of novel bile acid modulators to treat rare pediatric and adult
liver diseases, and other adult liver diseases and disorders.
Albireo’s lead product candidate, odevixibat, is being developed to
treat rare pediatric cholestatic liver diseases and is in Phase 3
development in progressive familial intrahepatic cholestasis (PFIC)
and biliary atresia, with a third Phase 3 trial being planned in
Alagille syndrome. The Company expects to complete IND-enabling
studies for new preclinical candidate A3907 this year. Albireo was
spun out from AstraZeneca in 2008 and is headquartered
in Boston, Massachusetts, with its key operating
subsidiary in Gothenburg, Sweden. The Boston
Business Journal named Albireo one of the 2020 Best Places to
Work in Massachusetts for the second consecutive year. For
more information on Albireo, please
visit www.albireopharma.com.
Media & Investor
contacts:Colleen Alabiso, 857-356-3905,
colleen.alabiso@albireopharma.com Hans Vitzthum, LifeSci Advisors,
LLC., 857-272-6177
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024